Interstitial lung disease in systemic lupus erythematosus

Gurtej S. Cheema, Francisco P. Quismorio

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Systemic lupus erythematosis (SLE) is a heterogenous disease of unknown etiology. It is not uncommon to see pleuropulmonary involvement in isolation or along with the involvement of other organ systems in SLE. Pulmonary manifestations of SLE can involve the pleura, lung parenchyma, airways, pulmonary vasculature, and the respiratory muscles. In this review we discuss two important pulmonary manifestations of SLE: acute lupus pneumonitis and diffuse interstitial lung disease. These two conditions have a major impact on the mortality and morbidity of patients with SLE and it is essential to recognize and treat them appropriately. High-resolution computed tomographic scans of the chest and pulmonary function tests help to establish a diagnosis and aid long-term follow-up of these patients. High-dose corticosteroids are the mainstay of treatment for the two conditions, although other agents such as cyclophosphamide, azathioprine, intravenous gamma globulin, and plasmapheresis have been used with varying degrees of success. (C) 2000 Lippincott Williams and Wilkins, Inc.

Original languageEnglish (US)
Pages (from-to)424-429
Number of pages6
JournalCurrent Opinion in Pulmonary Medicine
Volume6
Issue number5
StatePublished - 2000
Externally publishedYes

Fingerprint

Interstitial Lung Diseases
Systemic Lupus Erythematosus
Lung
Respiratory Muscles
Plasmapheresis
Pleura
gamma-Globulins
Respiratory Function Tests
Azathioprine
Cyclophosphamide
Pneumonia
Adrenal Cortex Hormones
Thorax
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Interstitial lung disease in systemic lupus erythematosus. / Cheema, Gurtej S.; Quismorio, Francisco P.

In: Current Opinion in Pulmonary Medicine, Vol. 6, No. 5, 2000, p. 424-429.

Research output: Contribution to journalArticle

@article{fc111bc734ba4c54b43fb14d64158c08,
title = "Interstitial lung disease in systemic lupus erythematosus",
abstract = "Systemic lupus erythematosis (SLE) is a heterogenous disease of unknown etiology. It is not uncommon to see pleuropulmonary involvement in isolation or along with the involvement of other organ systems in SLE. Pulmonary manifestations of SLE can involve the pleura, lung parenchyma, airways, pulmonary vasculature, and the respiratory muscles. In this review we discuss two important pulmonary manifestations of SLE: acute lupus pneumonitis and diffuse interstitial lung disease. These two conditions have a major impact on the mortality and morbidity of patients with SLE and it is essential to recognize and treat them appropriately. High-resolution computed tomographic scans of the chest and pulmonary function tests help to establish a diagnosis and aid long-term follow-up of these patients. High-dose corticosteroids are the mainstay of treatment for the two conditions, although other agents such as cyclophosphamide, azathioprine, intravenous gamma globulin, and plasmapheresis have been used with varying degrees of success. (C) 2000 Lippincott Williams and Wilkins, Inc.",
author = "Cheema, {Gurtej S.} and Quismorio, {Francisco P.}",
year = "2000",
language = "English (US)",
volume = "6",
pages = "424--429",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Interstitial lung disease in systemic lupus erythematosus

AU - Cheema, Gurtej S.

AU - Quismorio, Francisco P.

PY - 2000

Y1 - 2000

N2 - Systemic lupus erythematosis (SLE) is a heterogenous disease of unknown etiology. It is not uncommon to see pleuropulmonary involvement in isolation or along with the involvement of other organ systems in SLE. Pulmonary manifestations of SLE can involve the pleura, lung parenchyma, airways, pulmonary vasculature, and the respiratory muscles. In this review we discuss two important pulmonary manifestations of SLE: acute lupus pneumonitis and diffuse interstitial lung disease. These two conditions have a major impact on the mortality and morbidity of patients with SLE and it is essential to recognize and treat them appropriately. High-resolution computed tomographic scans of the chest and pulmonary function tests help to establish a diagnosis and aid long-term follow-up of these patients. High-dose corticosteroids are the mainstay of treatment for the two conditions, although other agents such as cyclophosphamide, azathioprine, intravenous gamma globulin, and plasmapheresis have been used with varying degrees of success. (C) 2000 Lippincott Williams and Wilkins, Inc.

AB - Systemic lupus erythematosis (SLE) is a heterogenous disease of unknown etiology. It is not uncommon to see pleuropulmonary involvement in isolation or along with the involvement of other organ systems in SLE. Pulmonary manifestations of SLE can involve the pleura, lung parenchyma, airways, pulmonary vasculature, and the respiratory muscles. In this review we discuss two important pulmonary manifestations of SLE: acute lupus pneumonitis and diffuse interstitial lung disease. These two conditions have a major impact on the mortality and morbidity of patients with SLE and it is essential to recognize and treat them appropriately. High-resolution computed tomographic scans of the chest and pulmonary function tests help to establish a diagnosis and aid long-term follow-up of these patients. High-dose corticosteroids are the mainstay of treatment for the two conditions, although other agents such as cyclophosphamide, azathioprine, intravenous gamma globulin, and plasmapheresis have been used with varying degrees of success. (C) 2000 Lippincott Williams and Wilkins, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033875511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033875511&partnerID=8YFLogxK

M3 - Article

C2 - 10958234

AN - SCOPUS:0033875511

VL - 6

SP - 424

EP - 429

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 5

ER -